13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01158183
(ClinicalTrials.gov)
July 20077/7/2010Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple SclerosisReal-World Betaseron® Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon ß-1b (Betaseron®) Given Every Other Day for Relapsing Forms of Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDrug: BAY86-5046_Interferon-beta-1bBayerNULLCompleted18 Years65 YearsBoth226N/AUnited States
2NCT00270816
(ClinicalTrials.gov)
November 200527/12/2005Interferon ß-1b Treatment by Cyclical AdministrationEffect of Cyclical Administration of Interferon ß-1b in Multiple Sclerosis - Comparison With Normal Dose.Multiple SclerosisDrug: Interferon-ß-1b;Drug: Interferon ß-1bS. Andrea HospitalItalian Multiple Sclerosis FoundationCompleted18 Years55 YearsAll60Phase 2;Phase 3Italy